SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-19-009207
Filing Date
2019-05-20
Accepted
2019-05-20 16:15:23
Documents
3
Period of Report
2019-05-20

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER f6k052019_enlivextherap.htm 6-K 16590
2 UNAUDITED HISTORICAL FINANCIAL INFORMATION FOR ENLIVEX AS OF MARCH 31, 2019 AND f6k052019ex99-1_enlivex.htm EX-99.1 226476
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS f6k052019ex99-2_enlivex.htm EX-99.2 85418
  Complete submission text file 0001213900-19-009207.txt   329724
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 19838919
SIC: 2834 Pharmaceutical Preparations